Past research has suggested that myo-inositol may benefit pregnant women with PCOS and reduce risk of complications. PCOS patients are prone to abnormal glucose regulation and myo-inositol has ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 ...

Researchers have successfully used a quantum algorithm to solve a complex century-old mathematical problem long considered ...

Journal of the Royal Statistical Society. Series C (Applied Statistics) Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in ...

Curis, Inc. ( NASDAQ: CRIS) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT ...

DURING the course of recent work at the West African Cacao Research Institute, it became necessary to evaluate the products of small-scale fermentations of different types of cacao. Hitherto, samples ...

Read about philanthropy’s response to new threats to the social sector; how community-led outcomes contracts are working for ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase I/IIa study titled A ...

The connection between education research, policy, and practice is broken. Here’s what it would take to fix it.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Explore Zentalis’ latest oncology advances and azenosertib updates for ovarian cancer from the 2025 Morgan Stanley Healthcare Conference.

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. Th ...